Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
Identifieur interne : 000459 ( PascalFrancis/Checkpoint ); précédent : 000458; suivant : 000460Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
Auteurs : Jan Balzarini [Belgique] ; Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Herman Egberink [Pays-Bas] ; Erik De Clercq [Belgique] ; Marc Van Ranst [Belgique] ; Svetlana S. Printsevskaya [Russie] ; Eugenia N. Olsufyeva [Russie] ; Svetlana E. Solovieva [Russie] ; Maria N. Preobrazhenskaya [Russie]Source :
- Antiviral research [ 0166-3542 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Antibiotique.
English descriptors
- KwdEn :
Abstract
Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivatives for FIPV or SARS-CoV.
Affiliations:
- Belgique, Pays-Bas, Russie
- District fédéral central, Province du Brabant flamand, Utrecht (province)
- Louvain, Moscou, Utrecht
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:06-0491667Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</title><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0491667</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0491667 INIST</idno><idno type="RBID">Pascal:06-0491667</idno><idno type="wicri:Area/PascalFrancis/Corpus">000452</idno><idno type="wicri:Area/PascalFrancis/Curation">000538</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000459</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000459</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</title><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibiotic</term><term>Antiviral</term><term>Feline infectious peritonitis virus</term><term>Glycopeptide</term><term>Human</term><term>Research and development</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term><term>Structure activity relation</term><term>Teicoplanin</term><term>Vancomycin</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Virus syndrome respiratoire aigu sévère</term><term>Glycopeptide</term><term>Antibiotique</term><term>Antiviral</term><term>Relation structure activité</term><term>Syndrome respiratoire aigu sévère</term><term>Vancomycine</term><term>Teïcoplanine</term><term>Virus péritonite infectieuse féline</term><term>Recherche développement</term><term>Eremomycine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Antibiotique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC<sub>50</sub>) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC<sub>50</sub> values of the glycopeptide derivatives for FIPV or SARS-CoV.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0></fA01><fA02 i1="01"><s0>ARSRDR</s0></fA02><fA03 i2="1"><s0>Antivir. res.</s0></fA03><fA05><s2>72</s2></fA05><fA06><s2>1</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</s1></fA08><fA11 i1="01" i2="1"><s1>BALZARINI (Jan)</s1></fA11><fA11 i1="02" i2="1"><s1>KEYAERTS (Els)</s1></fA11><fA11 i1="03" i2="1"><s1>VIJGEN (Leen)</s1></fA11><fA11 i1="04" i2="1"><s1>EGBERINK (Herman)</s1></fA11><fA11 i1="05" i2="1"><s1>DE CLERCQ (Erik)</s1></fA11><fA11 i1="06" i2="1"><s1>VAN RANST (Marc)</s1></fA11><fA11 i1="07" i2="1"><s1>PRINTSEVSKAYA (Svetlana S.)</s1></fA11><fA11 i1="08" i2="1"><s1>OLSUFYEVA (Eugenia N.)</s1></fA11><fA11 i1="09" i2="1"><s1>SOLOVIEVA (Svetlana E.)</s1></fA11><fA11 i1="10" i2="1"><s1>PREOBRAZHENSKAYA (Maria N.)</s1></fA11><fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>4 aut.</sZ></fA14><fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></fA14><fA20><s1>20-33</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18839</s2><s5>354000142223690030</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.1/2</s0></fA45><fA47 i1="01" i2="1"><s0>06-0491667</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Antiviral research</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC<sub>50</sub>) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC<sub>50</sub> values of the glycopeptide derivatives for FIPV or SARS-CoV.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Human</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Glycopeptide</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Glycopeptide</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Glicopéptido</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Antibiotique</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Antibiotic</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Antibiótico</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Antiviral</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Antiviral</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Antiviral</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Relation structure activité</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Structure activity relation</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Relación estructura actividad</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0><s2>NM</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0><s2>NM</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0><s2>NM</s2><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Vancomycine</s0><s2>NK</s2><s2>FR</s2><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Vancomycin</s0><s2>NK</s2><s2>FR</s2><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Vancomicina</s0><s2>NK</s2><s2>FR</s2><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Teïcoplanine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Teicoplanin</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Teicoplanina</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Virus péritonite infectieuse féline</s0><s2>NW</s2><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Feline infectious peritonitis virus</s0><s2>NW</s2><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Feline infectious peritonitis virus</s0><s2>NW</s2><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Recherche développement</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Research and development</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Investigación desarrollo</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Eremomycine</s0><s4>INC</s4><s5>86</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Peptide</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Peptides</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Péptido</s0><s5>37</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0><s5>38</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>38</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>38</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Poumon pathologie</s0><s5>39</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Lung disease</s0><s5>39</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>39</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Polypeptide</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Polypeptide</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Polipéptido</s0><s5>41</s5></fC07><fN21><s1>317</s1></fN21></pA></standard></inist><affiliations><list><country><li>Belgique</li><li>Pays-Bas</li><li>Russie</li></country><region><li>District fédéral central</li><li>Province du Brabant flamand</li><li>Utrecht (province)</li></region><settlement><li>Louvain</li><li>Moscou</li><li>Utrecht</li></settlement></list><tree><country name="Belgique"><region name="Province du Brabant flamand"><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name></region><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name></country><country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name></region></country><country name="Russie"><region name="District fédéral central"><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name></region><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000459 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000459 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:06-0491667
|texte= Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
}}
| This area was generated with Dilib version V0.6.33. |  |